Related Experiment Video
Updated: Apr 18, 2026

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
Published on: November 17, 2020
Cytomegalovirus meningoencephalitis after rituximab treatment for primary central nervous system lymphoma
Marina P Siakantaris1, Kimon V Argyropoulos, Savvas Ioannou
1*1st Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School †Immunology and HLA Histocompatibility Laboratory ‡Department of Neurology, Laiko General Hospital §Department of Hematology, Athens Medical Center-Psychikon Branch, Athens, Greece.
Abstract:
The efficacy and safety of rituximab against B-cell lymphomas is well established. However, there has been an increased incidence of infectious complications after rituximab treatment, mostly hepatitis B reactivation and progressive multifocal leukoencephalopathy. This is the case of a 67-year-old patient with primary central nervous system lymphoma, who developed cytomegalovirus meningoencephalitis after receiving high-dose chemotherapy and rituximab. As there was no evidence of lymphoma relapse or additional immunosuppression, besides his previous treatment, an association between rituximab and cytomegalovirus meningoencephalitis cannot be ruled out.
More Related Videos
Related Concept Videos
Cytomegalovirus Disease
Encephalitis l: Introduction
Viral Meningitis
Encephalitis ll: Pathophysiology

